GAMMA Investing LLC Buys Shares of 553 DaVita Inc. (NYSE:DVA)

GAMMA Investing LLC purchased a new position in DaVita Inc. (NYSE:DVA) during the 4th quarter, HoldingsChannel reports. The fund purchased 553 shares of the company’s stock, valued at approximately $60,000.

Several other large investors also recently bought and sold shares of DVA. Duality Advisers LP purchased a new stake in shares of DaVita in the fourth quarter valued at approximately $333,000. Handelsbanken Fonder AB grew its holdings in DaVita by 108.8% in the 4th quarter. Handelsbanken Fonder AB now owns 16,700 shares of the company’s stock valued at $1,749,000 after buying an additional 8,700 shares in the last quarter. CWM LLC increased its stake in shares of DaVita by 36.9% in the 4th quarter. CWM LLC now owns 1,537 shares of the company’s stock worth $161,000 after acquiring an additional 414 shares during the last quarter. abrdn plc boosted its position in shares of DaVita by 17.4% during the 4th quarter. abrdn plc now owns 168,316 shares of the company’s stock valued at $17,633,000 after acquiring an additional 24,966 shares during the last quarter. Finally, Federated Hermes Inc. grew its holdings in shares of DaVita by 6,158.3% in the fourth quarter. Federated Hermes Inc. now owns 77,979 shares of the company’s stock valued at $8,169,000 after purchasing an additional 76,733 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on DVA. UBS Group lifted their target price on shares of DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research note on Wednesday, February 14th. TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. StockNews.com upgraded shares of DaVita from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 25th. Truist Financial lifted their price objective on DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research note on Tuesday, February 20th. Finally, Barclays started coverage on shares of DaVita in a research report on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $118.50.

DaVita Stock Performance

Shares of DaVita stock opened at $139.75 on Thursday. The firm has a market capitalization of $12.26 billion, a P/E ratio of 18.89, a P/E/G ratio of 1.24 and a beta of 1.04. The company has a quick ratio of 1.13, a current ratio of 1.19 and a debt-to-equity ratio of 6.65. DaVita Inc. has a 52 week low of $71.51 and a 52 week high of $141.54. The firm’s 50 day moving average is $132.76 and its two-hundred day moving average is $111.76.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, February 13th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.53 by $0.34. The company had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.01 billion. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.11 earnings per share. Research analysts forecast that DaVita Inc. will post 9.23 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the sale, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other DaVita news, insider James O. Hearty sold 26,164 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the sale, the insider now directly owns 20,264 shares in the company, valued at approximately $2,424,384.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the transaction, the chief executive officer now owns 488,697 shares in the company, valued at $61,629,578.67. The disclosure for this sale can be found here. In the last three months, insiders have sold 134,540 shares of company stock valued at $16,551,071. Insiders own 1.40% of the company’s stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.